Annuncio pubblicitario
Italia markets closed

  • Dow Jones

    38.002,27
    -383,82 (-1,00%)
     

  • Nasdaq

    15.803,94
    -179,14 (-1,12%)
     

  • Nikkei 225

    38.405,66
    +470,90 (+1,24%)
     

  • EUR/USD

    1,0680
    -0,0045 (-0,42%)
     

  • Bitcoin EUR

    58.726,11
    -631,68 (-1,06%)
     

  • CMC Crypto 200

    1.291,32
    -47,75 (-3,57%)
     

  • HANG SENG

    17.763,03
    +16,12 (+0,09%)
     

  • S&P 500

    5.068,99
    -47,18 (-0,92%)
     

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023

Organogenesis Holdings Inc.
·1 minuto per la lettura
Organogenesis Holdings Inc.
Organogenesis Holdings Inc.

CANTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2023 financial results will be reported after the market closes on Thursday, November 9th.

Management will host a conference call at 5:00 p.m. Eastern Time on November 9th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.

CONTACT: Investor Inquiries: ICR Westwicke Mike Piccinino, CFA OrganoIR@westwicke.com Press and Media Inquiries: Organogenesis Ron O’Brien communications@organo.com